895-P: Testosterone Replacement Therapy in Men with Hypogonadism and Type 2 Diabetes—ABCD Worldwide Audit

Symptomatic testosterone deficiency is common affecting 40% of men with type 2 diabetes (T2D).1 Testosterone replacement therapy (TRT) has been shown to have benefits on reducing insulin resistance, improving glycemic control and relieving symptoms of hypogonadism.2,3,4 We present early data analysis from the Association of British Clinical Diabetologists (ABCD) Worldwide audit of Testosterone in men with T2D. The audit has already recruited 460 patients from 40 centres from 10 countries. Mean age 70.7 + 9.35 years, mean total testosterone 9.22 + 1.74nmol/l. TRT included parenteral lon-acting depot testosterone undeconoate and daily applied testosterone gels. All analysis by paired t-tests of parameters. HbA1c before and after TRT (1) 6 months 70.51 to 64.96 (n=163); (2) 12 months 70.82 to 61.06 (n=145) (3) 3 years 70.99 to 51.7 (n=125). Weight (kg) baseline 112.66kg at 3 years 107.15kg (p=0.61), Waist Circumference baseline 116.08cm to 115.12cm at 3 years (p=0.43). The Aging Male Symptom (AMS) Score is a marker of symptoms and quality of life. AMS score at baseline 40.83 after 12 months 21.93 (n=196) p